EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic ...

In connection with HekaBio’s recently announced strategic investment in NKGen, the partnership will expedite the regulatory, manufacturing, and commercial ...

PITTSBURGH, PA, USA I July 18, 2025 I Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, ...

First-in-human study of MOMA-341 focuses on advanced or metastatic solid tumors with high microsatellite instability - ...

LEXINGTON, MA, USA I July 16, 2025 I Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New ...

SEONGNAM, South Korea I July 17, 2025 I SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to ...

We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise. Target or technology pipeline and corporate benchmark analysis ...

The elritercept Phase 3 RENEW clinical trial (NCT06499285) is a global, randomized, double-blind, placebo-controlled trial in adults with transfusion-dependent anemia with very low, low, and ...

I Otsuka Pharmaceutical Co., Ltd. (Otsuka) has entered into an asset purchase agreement with Cantargia AB (Cantargia) for the acquisition of ...

The CARES clinical programme is the largest prospective investigation in cardiac AL amyloidosis to date with a total of 406 patients enrolled from 19 countries globally, including 281 patients with ...

LONDON, UK and NEW YORK, NY, USA I July 16, 2025 I OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing ...

New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the ...